Ashurst Perkins Coie

A judge has given the applicants in a case accusing two Sydney University academics of antisemitic comments more time to file a strike-out bid after a default, but said he was "sick and tired" of lawyers seeking forgiveness instead of permission.

Mallesons has asked a court to set aside an examination summons filed by the liquidators of defunct developer FSM against a former senior associate of the firm.

The former chief executive officer of Super Retail Group has argued he should have access to ASIC’s entire investigation file into the company, in proceedings alleging he failed to disclose a relationship with the company’s former chief human resources officer.

Investment firm White Oak has settled its case against IAG, Tokio Marine and subsidiary BCC alleging the insurers were liable for $200 million in damages following the collapse of supply chain finance company Greensill.

Swiss pharmaceutical company Actelion has brought a fourth patent infringement case over plans to launch a generic version of its blood pressure drug in Australia -- against Lupin unit Generic Health -- after firing off cases against three other drug makers. 

Mining giants BHP and Rio Tinto have failed to declass group proceedings over alleged failures to protect female employees from discrimination, but a judge struck out victimisation and sexual assault claims. 

Infrastructure fund manager Dexus must pay a total of $30 million in legal costs to Australia Pacific Airports Corporation and fellow APAC shareholders, after losing its case over a default notice that has forced a sale of Dexus' stake in the airport operator.

Optus has urged a court to make orders requiring group members to register for a data breach class action that covers 9.5 million people, but the lead applicant argues the case should remain open. 

In a change of heart, a judge has appointed two barristers to act as contradictors in argument over the funder's proposed $244 million cut of a record $750 million settlement in two Toyota class actions.

Cipla Australia wants an undertaking it intends to give pharma company Actelion over plans to launch a generic version of a blood pressure drug to be shielded from rivals Arrotex, Nova Pharmaceuticals and MSN Laboratories, as those companies battle patent infringement claims.